Human immunodeficiency virus (HIV)

The regional formulary will not cover all eventualities for infections medicines choices. As with any condition; patient specific factors and sensitivities need to be considered. Please consider this regional formulary advice alongside any relevant local Board guidelines.

Treatment of HIV

Prescribing Notes:

  • Antiretroviral therapy for chronic HIV infection should be initiated or altered only with the help of specialist advice available from a local HIV unit or sexual health service.
  • Antiretroviral therapy following an inoculation injury (post-exposure prophylaxis or PEP) if indicated should be commenced if possible within 2 hours and up to 72 hours after injury.
  • All treatments for HIV should be restricted to use by HIV specialists only.
  • Combination products may be used where considered appropriate to aid compliance.
  • HIV treatment should be prescribed in line with BHIVA Guidelines and recommendations from the SMC and NICE Multiple Technology Assessments.
  • HIV therapies have a narrow therapeutic range therefore patient adherence must be supported and drug interactions avoided.
  • When prescribing concurrent medication drug interactions should be checked at the HIV Drug Interactions website.

History Notes

30/07/2026

Regional formulary chapter launched.